ACADIA Pharmaceuticals Inc. Current Revenue (Deferred)

Current Revenue (Deferred) of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Revenue (Deferred) growth rates and interactive chart.


Highlights and Quick Summary

  • Current Revenue (Deferred) for the quarter ending March 30, 2017 was $4.13 Million (a 56.28% increase compared to previous quarter)
  • Year-over-year quarterly Current Revenue (Deferred) increased by 705.46%
  • Annual Current Revenue (Deferred) for 2016 was $2.64 Million (a 4707.27% increase from previous year)
  • Annual Current Revenue (Deferred) for 2013 was $55 Thousand (a -87.33% decrease from previous year)
  • Annual Current Revenue (Deferred) for 2012 was $434 Thousand (a -35.13% decrease from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Revenue (Deferred) of ACADIA Pharmaceuticals Inc.

Most recent Current Revenue (Deferred)of ACAD including historical data for past 10 years.

Interactive Chart of Current Revenue (Deferred) of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Current Revenue (Deferred) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2017 $4.13
2016 $2.64 $1.88 $0.51 $2.64
2014 $0.02 $0.03 $0.04
2013 $0.06 $0.08 $0.11 $0.14 $0.06
2012 $0.43 $0.27 $0.77 $0.68 $0.43
2011 $0.67 $0.71 $0.75 $0.46 $0.67
2010 $0.69 $6.68 $6.4 $0.69

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.